Cancer Clinical Trials Information Platform in Hong Kong


  1. This serves merely as an information platform about cancer clinical trials operated by different institutions in Hong Kong. HKACS is not responsible for the contents, availability and operability of the trials listed.
  2. Respective institutions usually reserve all rights regarding the implementation and execution of their respective clinical trials.
  3. Patients usually need to satisfy a complex and stringent set of selection criteria before being selected/ included in certain clinical trials. Interested parties should contact respective institutions regarding further details of the trials


Cancer Site


*in alphabetical order (Last updated on 29/6/2022)


Nasopharyngeal Cancer

Institution Study Title  
HKU A multi-centre phase II randomized-controlled study on addition of durvalumab (MEDI4736) to induction chemotherapy and concurrent chemoradiation and followed by maintenance durvalumab for locoregionally advanced nasopharyngeal carcinoma Click for Details
CUHK Randomized Phase II and Phase III Studies of Individualized Treatment for Nasopharyngeal Carcinoma Based on Biomarker Epstein Barr Virus (EBV) Deoxyribonucleic Acid (DNA) Click for Details
CUHK NEO-SPACE trial: Neoadjuvant Pembrolizumab-Gemcitabine-Cisplatin followed by Concurrent Pembrolizumab-Chemoradiation and Maintenance Pembrolizumab for Stage IVA Nasopharyngeal Cancer Click for Details
CUHK A phase III, randomized, double-blind, placebo controlled study of atezolizumab plus triagolumab in combination with paclitaxel and cisplatin compared with paclitaxel and cisplatin as first-line treatment in patients with unresectable locally advanced, unresectable recurrent, or metastatic esophageal squamous cell carcinoma Click for Details
CUHK AXEL: Axitinib-Avelumab combination in recurrent or metastatic nasopharyngeal cancer: a multicenter phase 2 trial Click for Details
CUHK An Open-Label, Multicenter Phase 1b/2 Study of Nanatinostat and Valganciclovir in Patients with Advanced Epstein-Barr Virus-Positive (EBV+) Solid Tumors and in Combination with Pembrolizumab in Patients with Recurrent/Metastatic Nasopharyngeal Carcinoma Click for Details
CUHK A phase 2 trial of TAS 102 in recurrent/metastatic nasopharyngeal carcinoma Click for Details


For Enquiry, please contact the respective institute, HKACS is not responsible for the outcomes of the clinical trials.